G2A RECEPTOR AS A THERAPEUTIC TARGET

摘要

The present disclosure is directed to methods of treating and preventing disease states and conditions associated with or characterized by decreased high-density lipoprotein (HDL) particle levels, increased very-low density lipoprotein (VLDL) particle levels and/or increased low-density lipoprotein (LDL) particle levels. In one embodiment, such treatment and prevention methods involve modulating the expression levels and/or activity of the G2A receptor or a polypeptide regulated by the G2A receptor. The present disclosure is also directed to diagnostic methods for identifying subjects suffering from or at risk for such disease states and conditions. Furthermore, the present disclosure is directed to methods for identifying compounds that modulate the expression levels and/or activity of the G2A receptor or the signaling pathway in which the G2A receptor takes part.